0 results for 'Eli Lilly'
For more than 40 years, California was out of synch with the U.S. Supreme Court, permitting defendants in state antitrust actions to argue that direct purchasers suffered no harm because they passed price increases on to consumers. With a ruling Monday that eliminates the pass-through defense, California's now in step with the federal courts.
Federal Circuit Strengthens Patent Protection for Research Tools
In Integra Lifesciences I, Ltd. v. Merck KgaA, the U.S. Court of Appeals for the Federal Circuit dramatically narrowed the safe harbor from patent infringement afforded to drug developers under 35 U.S.C. � 271(e)(1) -- the "safe harbor" provision of the Hatch-Waxman Act -- and restored the vitality of patent rights with respect to research tools.Daily Decision Service Alert: Vol. 19, No. 162 - August 24 2010
Daily decision alert.Awash in Vioxx Suits, Merck Is Recruiting Big-Time Help
Arming for a looming courtroom battle over its Vioxx arthritis drug, Merck & Co. has hired a handful of firms for its defense. The lead firm could receive as much as $50 million for its work on Vioxx litigation, according to observers. In addition to the financial considerations, the task of compiling an outside legal team may present special challenges for a company that highly values privacy and prefers to turn to its in-house lawyers.Problems With the Patent System: Nothing Cash Can't Cure
A new patent reform bill was introduced in Congress on April 18, and the lobbyists are circling. Some points receive nearly unanimous support -- the Patent and Trademark Office is overburdened, and it's time for America to dump its unique first-to-invent system for the first-to-file system common in the rest of the world -- but others are the subject of hot debate. High-tech companies are spending more than ever to convince legislators that change is good, but what's really needed depends on who you ask.Direct to Consumer Pharma Marketing, Tonight on 'The American Law Journal'
American doctors wrote more than 164 million prescriptions for antidepressants in 2008. How much was that due to direct to consumer drug advertising? Aside from the moral questions, how does that advertising affect pharmaceutical product litigation and what happens in the courtroom?State AI Legislation Is on the Move in 2024
Brought to you by LexisNexis®
Download Now
2024 ESI Risk Management & Litigation Readiness Report
Brought to you by Pagefreezer
Download Now
Creating a Culture of Compliance
Brought to you by Ironclad
Download Now
A Buyer's Guide to Law Firm Software
Brought to you by PracticePanther
Download Now